Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

479.35 +5.69 (+1.20%)
Streaming Delayed Price Updated: 12:59 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 139,087
Open 474.68
Bid (Size) 478.39 (40)
Ask (Size) 480.40 (120)
Prev. Close 473.66
Today's Range 470.04 - 486.33
52wk Range 266.98 - 519.99
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
6 Stock Ideas for the Next 5 Years ↗
Listen in as Motley Fool co-founder Tom Gardner and Chief Investment Officer Andy Cross talk about stocks! 
Via The Motley Fool
Topics Artificial Intelligence
United Therapeutics Corp. (NASDAQ:UTHR) Passes the "Caviar Cruise" Quality Investing Screen ↗
Via Chartmill

Performance

YTD
-3.5%
-3.5%
1 Month
+2.4%
+2.4%
3 Month
+1.6%
+1.6%
6 Month
+52.6%
+52.6%
1 Year
+28.6%
+28.6%

More News

Read More
News headline image
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack
Via StockStory
Topics Artificial Intelligence
News headline image
$100 Million Exit: Why One Fund Walked Away From a Chinese E-Commerce Stock Up 24% ↗
Via The Motley Fool
Topics Economy
News headline image
This Bank Stock Just Saw a $24 Million Fund Sale, but Here's Why It's Still a Top Holding ↗
Via The Motley Fool
Topics Credit Cards ETFs
News headline image
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Market-Beating Stocks to Target This Week
Via StockStory
Topics Credit Cards Supply Chain
News headline image
Investment Advisor Doubles Down on Insurance Stock, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Bonds Regulatory Compliance
News headline image
Nepsis Bets on CAVA's Future Growth Plan With $2.9 Million Purchase ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Cash-Heavy Stocks to Target This Week and 1 We Question
Via StockStory
News headline image
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
Via StockStory
Topics Artificial Intelligence
News headline image
Why a $27 Million Buy Signals New Confidence in Weatherford Stock ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Value Fund Has a $29 Million Bet on Core Natural Resources Stock ↗
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
United Therapeutics Corp (NASDAQ:UTHR): A Value Investing Case Study ↗
Via Chartmill
News headline image
United Therapeutics Corp (NASDAQ:UTHR): A Caviar Cruise Quality Investment ↗
Via Chartmill
News headline image
2 Mooning Stocks on Our Buy List and 1 That Underwhelm
Via StockStory
News headline image
Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today ↗
Via Benzinga
News headline image
United Therapeutics Corp (NASDAQ:UTHR) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
3 Reasons Investors Love United Therapeutics (UTHR)
Via StockStory

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 479.35
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 02/17/26 12:59 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 21.52B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 22B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.